Integrated chemical profiling and lipidomics reveal that Mailuoning oral liquid alleviates diet-induced MASLD via PPARα-mediated lipid homeostasis and COX-2 inhibition, with identification of potential active constituents
5 affiliations
- 1Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, The MOE Key Laboratory for Standardization of Chinese Medicines
- 2Department of Pharmacy, The SATCM Third Grade Laboratory of Traditional Chinese Medicine Preparations, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- 3Institute of Chinese Medicinal Materials, Gansu Academy of Agricultural Sciences
- 4Department of Pharmaceutics, China Pharmaceutical University
- 5Technology Center of Jinling Pharmaceutical Co., Ltd.
Abstract
Background: Mailuoning oral liquid (MLN), a standardized five-herb formula, is used for ischemic vascular diseases and shows potential in ameliorating dyslipidemia. Our previous study showed MLN alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) via peroxisome proliferator-activated receptor α (PPARα) activation, but its comprehensive chemical profile, systemic exposure, and bioactive constituents mediating both PPARα activation and cyclooxygenase-2 (COX-2) inhibition remain unclear.
Methods: High-fat, high-fructose diet-fed rats received MLN (5.4 or 10.8 mL/kg/day) for 8 weeks. Ultra-high-performance liquid chromatography coupled with Q-Exactive Orbitrap high-resolution mass spectrometry (UHPLC-Q-Exactive Orbitrap HRMS) profiled MLN chemicals and identified serum/liver prototypes. Biochemical profiles, glucose tolerance, histopathology, untargeted lipidomics, and targeted polyunsaturated fatty acid (PUFA) analysis were performed. PPARα and COX-2 signaling were examined by quantitative real-time polymerase chain reaction (qPCR), western blotting, and immunohistochemistry. Key constituents were screened for PPARα activation via dual luciferase reporter assay and molecular docking; COX-2 inhibition was validated by enzyme assays and molecular dynamics.
Results: A total of 143 compounds were characterized; 48 and 92 prototypes were enriched in serum and liver, respectively. MLN ameliorated dyslipidemia, glucose intolerance, steatosis, and inflammation. Lipidomics revealed bidirectional modulation of hepatic lipids, reversing triglyceride (TAG) accumulation and restoring phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) levels. Targeted analysis showed increased eicosapentaenoic acid (EPA) and normalized COX-2-derived prostaglandins (PGD ₂ , PGE ₂ ). MLN activated hepatic PPARα and downregulated COX-2. Seven serum-enriched compounds (chlorogenic acid, macranthoidin B, luteoloside, harpagide, angoroside C, oleanolic acid, betaine) were validated as direct PPARα agonists. Secologanoside and chikusetsusaponin IVa were identified as novel COX-2 inhibitors (half-maximal inhibitory concentration (IC ₅₀ ) = 14.61 and 120.9 nM).
Discussion: MLN alleviates MASLD via dual PPARα activation and COX-2 inhibition, providing a mechanistic foundation for repurposing this herbal formula in early-stage MASLD.
Related
- Spatial Lipidomics and Transcriptomics Reveal Nicotine-Mediated Restoration of Lipid Homeostasis in Parkinson’s Disease
- A Scalable, Traceable Computational-to-Experimental Pipeline for Activity-Guided Identification of Bioactive Constituents: A Case Study in Salvia miltiorrhiza Bunge.
- Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation
- Spatial lipidomics in gynecologic malignancies: molecular identification, cellular attribution, and mechanistic validation.
- Integrated oculomics and lipidomics characterise cross-sectional retinal–lipidomic associations in a generally healthy biobank population
BibTeX
@article{wu2026integrated,
title = {{Integrated chemical profiling and lipidomics reveal that Mailuoning oral liquid alleviates diet-induced MASLD via PPARα-mediated lipid homeostasis and COX-2 inhibition, with identification of potential active constituents}},
author = {Sijia Wu and Wangya Jia and Xun Zhou and Linyan Zhu and Keke Wang and Jian Li and Lili Ji and Wei Liu and Hong Xu},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1939197},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1939197/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Integrated chemical profiling and lipidomics reveal that Mailuoning oral liquid alleviates diet-induced MASLD via PPARα-mediated lipid homeostasis and COX-2 inhibition, with identification of potential active constituents
AU - Sijia Wu
AU - Wangya Jia
AU - Xun Zhou
AU - Linyan Zhu
AU - Keke Wang
AU - Jian Li
AU - Lili Ji
AU - Wei Liu
AU - Hong Xu
PY - 2026
DA - 2026/10/29
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1939197
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1939197/full
AB - Background: Mailuoning oral liquid (MLN), a standardized five-herb formula, is used for ischemic vascular diseases and shows potential in ameliorating dyslipidemia. Our previous study showed MLN alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) via peroxisome proliferator-activated receptor α (PPARα) activation, but its comprehensive chemical profile, systemic exposure, and bioactive constituents mediating both PPARα activation and cyclooxygenase-2 (COX-2) inhibition remain unclear. Methods: High-fat, high-fructose diet-fed rats received MLN (5.4 or 10.8 mL/kg/day) for 8 weeks. Ultra-high-performance liquid chromatography coupled with Q-Exactive Orbitrap high-resolution mass spectrometry (UHPLC-Q-Exactive Orbitrap HRMS) profiled MLN chemicals and identified serum/liver prototypes. Biochemical profiles, glucose tolerance, histopathology, untargeted lipidomics, and targeted polyunsaturated fatty acid (PUFA) analysis were performed. PPARα and COX-2 signaling were examined by quantitative real-time polymerase chain reaction (qPCR), western blotting, and immunohistochemistry. Key constituents were screened for PPARα activation via dual luciferase reporter assay and molecular docking; COX-2 inhibition was validated by enzyme assays and molecular dynamics. Results: A total of 143 compounds were characterized; 48 and 92 prototypes were enriched in serum and liver, respectively. MLN ameliorated dyslipidemia, glucose intolerance, steatosis, and inflammation. Lipidomics revealed bidirectional modulation of hepatic lipids, reversing triglyceride (TAG) accumulation and restoring phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) levels. Targeted analysis showed increased eicosapentaenoic acid (EPA) and normalized COX-2-derived prostaglandins (PGD ₂ , PGE ₂ ). MLN activated hepatic PPARα and downregulated COX-2. Seven serum-enriched compounds (chlorogenic acid, macranthoidin B, luteoloside, harpagide, angoroside C, oleanolic acid, betaine) were validated as direct PPARα agonists. Secologanoside and chikusetsusaponin IVa were identified as novel COX-2 inhibitors (half-maximal inhibitory concentration (IC ₅₀ ) = 14.61 and 120.9 nM). Discussion: MLN alleviates MASLD via dual PPARα activation and COX-2 inhibition, providing a mechanistic foundation for repurposing this herbal formula in early-stage MASLD.
SN - 1663-9812
ER -